• PDF / 169,773 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 116 Downloads / 141 Views

DOWNLOAD

REPORT

---

1 S

Antineoplastics/filgrastim/pegfilgrastim Aortitis and lack of efficacy: 9 case reports

A study described 9 patients (including 5 women and 3 men) aged 44–72 years, who were identified from Vigibase database. Of whom 6 patients developed aortitis during treatment with filgrastim, pegfilgrastim or nivolumab. Additionally, the remaining 3 pateints exhibited treatment failure during treatment with rituximab or tocilizumab for aortitis, rheumatoid aortitis or granulomatosis with polyangiitis [routes, dosages, durations of treatments to reactions onsets and outcomes not stated; not all indications stated]. The patients were reported in the WHO pharmacovigilance database of Spain, USA, Greece, Canada, Japan or Sweden. Out of the 9 pateints, 4 patients, who had been receiving nivolumab for malignant melanoma (one patient), lung cancer (two patients) and unknown indication (one patient), developed aortitis. Out of the remaining 5 pateints, 2 patients had been receiving trastuzumab for breast cancer. These 2 patients had been receiving docetaxel, filgrastim, pertuzumab, piperacillin/tazobactam, pegfilgrastim, cyclophosphamide or unspecified drug concomitantly. Out of these 2 pateints, one developed filgrastim-induced aortitis and other patient developed pegfilgrastim-induced aortitis. Out of the remaining 3 patients, one patients had been receiving rituximab for granulomatosis with polyangiitis. However, treatment failure was noted. The remaining two patients had been receiving tocilizumab for rheumatoid aortitis (one patient) and aortitis (one patient); but the patients exhibited treatment failure. Mettler C, et al. Antineoplastic drug-induced aortitis: An unraveled adverse effect using the world health organization pharmacovigilance database. The Journal of Rheumatology 47: 1298-1300, No. 8, Aug 2020. Available from: URL: http://doi.org/10.3899/jrheum.200023

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

803515111

Reactions 14 Nov 2020 No. 1830